|drug1481||Hydroxychloroquine + placebo Wiki||1.00|
|drug2694||Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index Wiki||1.00|
|drug1619||Informed consent Wiki||1.00|
|D011024||Pneumonia, Viral NIH||0.11|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
Double blinded randomized clinical trial designed to evaluate the efficacy and safety of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with confirmed COVID-19 pneumonia.
Description: Evaluation of the clinical status of patient defined by the Ordinal Scale of 7 points (score range from 1 to 7 , with 7 being the worst score)Measure: Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment). Time: up to Day 11
Description: Evaluation of the clinical status of patient defined by the Ordinal Scale of 7 points at day 15 and day 29Measure: Clinical status assessed by ordinal scale Time: up to Day 29
Description: Necessity for transfer to Intensive care unitMeasure: transfer to ICU Time: up to Day 29
Description: days from admission to hospital dischargeMeasure: Length of hospital day Time: up to Day 29
Description: incidence of all-cause mortalityMeasure: Hospital Mortality Time: Day 29
Description: Need to mechanical ventilationMeasure: Need to Mechanical Ventilation Time: up to Day 29
Description: adverse reactionsMeasure: Occurence of grade 3-4 adverse event Time: up to Day 29
Description: ECGMeasure: QTc Lengthening Time: up to Day 11
Description: Thoracic CT scan : number and size of ground-glass opacifications on day 1 and day 11 Two independent pulmonary imagery experts will assess abnormalities according to a standardized frameworkMeasure: Evolution of pulmonary CT scan images Time: up to Day 11
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports